Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib

We describe here the case of a 40-years-old woman diagnosed as having chronic phase chronic myeloid leukemia and treated with standard dose of imatinib; the patient obtained the complete cytogenetic remission in 7 months, but she failed to achieve major molecular response (MMolR) after more than18 m...

Full description

Bibliographic Details
Main Author: Mario Annunziata
Format: Article
Language:English
Published: SEEd 2015-10-01
Series:Clinical Management Issues
Subjects:
Online Access:https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1122